NSESpurt in Volume9 Sept 2026 · 9 Sept 2026, 08:36 pm

Spurt in Volume

CORONA Remedies Limited · CORONA

✦ AI SummaryRegulatory

CORONA Remedies Limited has submitted a response to the National Stock Exchange of India Limited regarding a significant increase in volume, stating that the company is in compliance with listing obligations and has made all necessary disclosures.

Analysis Scores

Earnings Impact5/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Significant increase in volume has been observed in CORONA Remedies Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. CORONA Remedies Limited has submitted their response.

Attachments (1)

📄

CORONAREMEDIES_09092026202039_NSEclarification.pdf

pdf

Download →
View document text
September 09, 2026 Assistant Manager – Surveillance National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai-400051 (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Clarification on movement in volume This has reference to your email and letter dated September 09, 2026 seeking clarification on movement in volume. We would like to inform you that the Company is in compliance with the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015 and has been promptly informing the Stock Exchanges on all events and information, which have a bearing on operation or performance of the Company. There is no undisclosed / price sensitive information or any impending announcement / corporate action which needs to be informed to the exchange at this point of time. We further wish to clarify that, increase in the volume of the Company’s shares is purely market driven. The Company has made and will continue to make disclosures in compliance with its obligations under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirement) Regulations, 2015. You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer